Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
نویسندگان
چکیده
Unlike chemoimmunotherapy regimens, which are given for a defined period, ibrutinib, a first-in-class Bruton's kinase inhibitor, allows most patients with CLL to remain on treatment for an extended period. Our experience, supported by sequential CT scan images, suggests that long-term ibrutinib promotes a high response rate that improves in quality with time.
منابع مشابه
Three-year follow-up of treatment-naı̈ve and previously treated patients with CLL and SLL receiving single-agent ibrutinib
• Three-year follow-up of ibrutinib in CLL demonstrated continued activity with durable responses that improve in quality with extended treatment. • Toxicity diminished over time with respect to grade $3 cytopenias, fatigue, infections, and adverse events leading to discontinuation. Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemoki...
متن کاملSuccessful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant
Patients with chronic lymphocytic leukemia (CLL) who progress to Richter transformation (RT) have a poor prognosis. Multi-agent chemotherapy regimens do not have good response rates. There are few case reports on the use of ibrutinib in RT. Here, we present a patient who was heavily pretreated for CLL, including allogeneic stem cell transplant, and progressed to RT. She had a mixed response to ...
متن کاملEffect of curcumin on growth inhibition and gene expression reduction in chronic lymphocytic leukemia cells (CLL-CII)
Introduction: Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in adults living in Western countries. with a diverse clinical course that due to life expectancy less than two years between patients finding ,new therapeutic strategies is essential for it. Curcumin as the biologic active of turmeric, has many biological properties such as anti-inflammatory, anti-oxidant, anti-diab...
متن کاملThe HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Ibrutinib is an orally administered, covalent inhibitor of Bruton's tyrosine kinase with activity in B-cell malignancies based on Phase I/II studies. We describe the design and rationale for the Phase III HELIOS trial (trial registration: EudraCT No. 2012-000600-15; UTN No. U1111-1135-3745) investigating whether ibrutinib added to bendamustine and rituximab (BR) provides benefits over BR alone ...
متن کاملQuality of Life of Patients with Different Types of Leukemia
Background: Leukemia is one of the major causes of mortality and disability and the seventh most prevalent cancer worldwide. It has various effects on different aspects of physical, psychological, reproductive, social, and economic performance of human life. This study compared the quality of life of patients with different types of leukemia hospitalized in Ayatollah Khansari Hospital in Arak- ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 5 شماره
صفحات -
تاریخ انتشار 2017